Results 151 to 160 of about 61,480 (319)
QSAR development and profiling of 72,524 REACH substances for PXR activation and CYP3A4 induction
, 2017 Sine Abildgaard Rosenberg +5 more
openalex +1 more source
Clinical Pharmacology &Therapeutics, Volume 119, Issue 3, Page 629-640, March 2026.Momelotinib, a Janus kinase (JAK) 1/JAK2/activin A receptor type 1 inhibitor, is approved for the treatment of myelofibrosis with anemia. These analyses characterized the population pharmacokinetics of momelotinib and its active metabolite M21 following administration of the commercial tablet formulation in patients with myelofibrosis from phase II/III
Benjamin Rich +5 more
wiley +1 more source
Impact of Pomegranate Juice on the Pharmacokinetics of CYP3A4- and CYP2C9-Mediated Drugs Metabolism: A Preclinical and Clinical Review [PDF]
, 2023 Kenza Mansoor +6 more
openalex +1 more source
New Zealand Journal of Botany, Volume 64, Issue 1, March 2026.SARS‐CoV2 Omicron and its substrains are still a critical global health issue and extremely contagious, even with widespread vaccination efforts. Hospitalizations and mortality rates linked to these variants are still prevalent. Current therapeutic options face challenges, including low effectiveness, suboptimal pharmacokinetics, and drug resistance ...
Frank Eric Tatsing Foka +1 more
wiley +1 more source
Psychiatry and Clinical Neurosciences Reports, Volume 5, Issue 1, March 2026.Abstract Background Valbenazine is used to treat dyskinesia and is generally associated with limited side effects; however, a few cases with the adverse effect of parkinsonism are reported in the literature. In this study, we report a case of valbenazine‐induced acute parkinsonism.
Yasuhito Nagai +2 more
wiley +1 more source